Diffusion Pharmaceuticals LLC is a drug discovery and development company commercializing a pipeline of proprietary compounds from the novel trans bipolar carotenoid family of molecules. Diffusion's lead compound, trans sodium crocetinate (designated as DP-00-01, and often referred to as TSC) is currently in the late pre-clinical stage of development to treat oxygen deficiency at the cellular level across a variety of life-threatening conditions. This oxygen deficiency, known by the medical term “hypoxia,” is implicated in hemorrhage, stroke, heart attack, congestive heart failure, respiratory disorders, certain cancerous tumors and other conditions.
Diffusion Pharmaceuticals Address
1317 Carlton Ave Charlottesville, VA United States